Affinia Therapeutics Highlights Advances in Gene Therapy Pipeline and Manufacturing at ASGCT 2026
Affinia Therapeutics showcased major progress across its cardiovascular and central nervous system gene therapy programs during multiple presentations at the 29th Annual Meeting of the American Society of Gene & Cell Therapy in Boston. The company unveiled new preclinical and translational data supporting its lead investigational therapy AFTX-201 for BAG3-associated dilated cardiomyopathy (DCM), detailed the design of its upcoming Phase 1/2 UPBEAT clinical trial, and highlighted advances in its proprietary adeno-associated virus (AAV) capsid engineering and manufacturing platform technologies.
The presentations collectively underscored Affinia’s ambition to establish itself as a leader in next-generation gene therapies targeting severe cardiovascular, skeletal muscle, and neurological disorders. The company’s research focused particularly on improving tissue targeting, lowering therapeutic doses, enhancing manufacturing scalability, and expanding the therapeutic potential of AAV-based medicines.
At the center of the company’s ASGCT presentations was AFTX-201, an investigational one-time gene therapy being developed for patients with BAG3-associated dilated cardiomyopathy, a rare inherited heart disease that can lead to progressive heart failure and premature death. BAG3 DCM is caused by mutations in the BAG3 gene, which plays a critical role in maintaining cardiac muscle integrity and cellular stress responses. Patients with BAG3 mutations often experience worsening cardiac dysfunction over time, and currently available therapies primarily manage symptoms rather than addressing the underlying genetic cause of the disease.
Affinia designed AFTX-201 to deliver a fully human, full-length BAG3 transgene using one of the company’s proprietary engineered AAV capsids optimized for highly efficient cardiac transduction. According to the company, the engineered vector allows therapeutic activity at doses that are approximately five- to ten-fold lower than those commonly associated with conventional AAV capsids such as AAV9 or AAVrh74. Lower dosing may offer significant safety advantages by potentially reducing immune-related toxicities and off-target effects that have challenged the broader gene therapy field.
The investigational treatment is administered through a single intravenous infusion and is intended to provide durable restoration of BAG3 protein expression in heart tissue. Preclinical studies presented at ASGCT demonstrated that AFTX-201 substantially increased BAG3 protein levels in the heart and restored cardiac function in animal models of BAG3-associated DCM.
Among the most important findings presented at the conference were new data from BAG3 haploinsufficient mouse models with established disease. These animals already exhibited measurable cardiac dysfunction and structural abnormalities before treatment initiation. Researchers reported that a single intravenous dose of AFTX-201 at 9e11 vector genomes per kilogram produced complete correction of cardiac function and structural abnormalities eight weeks after administration.
Additional pharmacokinetic analyses showed durable transgene expression in cardiac tissue beginning 14 days after dosing and continuing through 140 days post-treatment, representing the duration of the mouse study and effectively spanning the animals’ lifespan. The long-lasting expression supports the concept that AFTX-201 could potentially function as a durable one-time therapy.
The company also presented encouraging translational data from non-human primate studies. Researchers observed sustained gene transfer and transgene expression for up to six months following treatment. Importantly, the doses being advanced into human clinical testing generated levels of cardiac gene transfer in primates comparable to those associated with therapeutic efficacy in the mouse disease model.
Affinia emphasized the safety profile observed during the preclinical program. Toxicology evaluations indicated that AFTX-201 was generally well tolerated in both mice and non-human primates. No treatment-related deaths or major adverse effects were reported. Investigators noted the absence of clinically significant elevations in liver function markers, a common concern in systemic AAV therapies. In addition, no signs of complement activation were observed in non-human primates, even without prophylactic immunosuppressive therapy.
These findings may be especially important for the future clinical development of systemic gene therapies because immune-mediated complications have emerged as a major challenge for several high-dose AAV programs across the biotechnology industry.
Affinia also reported results from a direct comparison study evaluating its proprietary capsid against a traditional AAV vector approach. In the head-to-head analysis, AFTX-201 administered at 9e11 vg/kg restored cardiac function in BAG3 haploinsufficient mice, while an identical gene construct delivered using the conventional AAVrh74 capsid failed to produce comparable therapeutic benefit at the same dose.
The company believes these data highlight the potential superiority of its engineered capsid technology in delivering efficient cardiac gene transfer while minimizing exposure levels.
The preclinical and translational findings were featured in an oral presentation delivered by Giri Murlidharan, Ph.D., senior director of translational biology at Affinia Therapeutics during the ASGCT meeting.
Hideo Makimura, M.D., Ph.D., chief medical officer of Affinia, said the company believes AFTX-201 has the potential to become a transformative therapy capable of restoring cardiac function and reversing heart failure progression in patients with BAG3-associated DCM.
Makimura stated that the program has demonstrated differentiated efficacy and improved safety compared with therapies relying on conventional AAV capsids. He noted that the ASGCT data support the dose levels selected for the company’s first-in-human Phase 1/2 UPBEAT clinical trial.
Affinia also announced that it is in advanced discussions with approximately 10 potential clinical trial sites across the United States and Canada. The company indicated that Houston Methodist Hospital is expected to become the first participating site in the UPBEAT study.
Arvind Bhimaraj, M.D., M.P.H., an advanced heart failure cardiologist and physician scientist at Houston Methodist Hospital, described BAG3-associated DCM as a major unmet medical need because patients experience rapidly progressive cardiac dysfunction and currently lack therapies that directly target the root cause of disease. He expressed optimism about the investigational therapy and the institution’s participation in the clinical trial.
Affinia also used ASGCT to present details regarding the design of the Phase 1/2 UPBEAT trial. The study is structured as a multicenter, open-label, single-arm clinical trial evaluating AFTX-201 in adults with genetically confirmed BAG3-associated dilated cardiomyopathy.
The trial will consist of an initial dose-exploration stage followed by a dose-expansion phase. All participants will receive a single intravenous administration of AFTX-201 at doses supported by preclinical safety and efficacy data. The primary objective is to assess safety and tolerability during the first 52 weeks after treatment. Secondary and exploratory endpoints will include pharmacodynamic measurements and preliminary indicators of clinical efficacy compared with baseline assessments.
Affinia said the initial cohort is expected to enroll three to five patients. Eligible participants include adults between 18 and 55 years old who carry a BAG3 mutation and experience limitations in normal physical activity due to heart disease.
Beyond its lead cardiovascular program, Affinia also highlighted advancements in manufacturing and vector engineering technologies that could support a broader pipeline of genetic medicines.
One oral presentation focused on the company’s proprietary high-yield AAV manufacturing platform. Affinia reported that the process was successfully transferred to Forge Biologics for Good Manufacturing Practice production of AFTX-201.
According to the company, the manufacturing campaign achieved harvest titers exceeding 6e15 vector genomes per liter, surpassing many industry benchmarks for AAV production efficiency. Affinia stated that the process may ultimately support commercial-scale manufacturing capable of supplying therapies for thousands of patients annually using relatively modest bioreactor volumes ranging from 50 to 250 liters.
The company also presented data regarding the development and qualification of product-specific analytical methods designed to characterize the quality, potency, and consistency of AFTX-201 clinical material. These analytical capabilities are expected to support future product development efforts across Affinia’s broader platform.
In the neuroscience field, Affinia presented progress involving its blood-brain-barrier-penetrant capsids. One poster described the ATC-134 capsid, which achieved robust neuronal transduction across more than 90% of neurons in non-human primate brains following low-dose systemic administration.
Researchers observed transduction throughout cortical regions, deep brain structures, and the spinal cord at a dose of 3e13 vg/kg administered intravenously. The findings suggest the capsid may support development of systemic gene therapies for a variety of neurological diseases while potentially reducing the need for invasive delivery approaches.
Affinia additionally highlighted collaborative work with Modalis Therapeutics focused on developing a potential gene therapy for Myotonic Dystrophy Type 1. The collaboration combines Affinia’s myotropic capsid ATC-187 with Modalis’ epigenetic editing payload technology in an effort to create a next-generation treatment for the neuromuscular disorder.
The company’s extensive ASGCT presence reflects growing momentum for Affinia as it transitions toward clinical-stage development. Regulatory progress has also accelerated in recent months. Earlier in 2026, the U.S. Food and Drug Administration accepted the Investigational New Drug application for AFTX-201 and granted the therapy Fast Track designation. Additionally, the European Medicines Agency awarded Orphan Drug designation for the program, while Health Canada approved the company’s Clinical Trial Application to begin studies in Canada.
As gene therapy development continues evolving toward more precise and efficient delivery systems, Affinia’s presentations at ASGCT 2026 demonstrated the company’s focus on solving several of the industry’s most pressing challenges, including tissue specificity, safety, scalability, and long-term durability. With the UPBEAT study expected to begin enrolling patients soon, AFTX-201 could become an important test case for whether next-generation engineered AAV capsids can improve both the efficacy and safety profile of systemic gene therapies targeting cardiovascular disease.
About BAG3 DCM
BAG3 dilated cardiomyopathy (DCM) is a serious, inherited heart condition with a high mortality rate and a significant unmet medical need. The disease affects more than 70,000 patients in Canada and the E.U., U.K., and U.S. regions. The BAG3, or Bcl2-associated athanogene 3, gene encodes for a protein that is critical to the normal structure and function of heart cells. Patients with BAG3 DCM have a mutation in the BAG3 gene and a deficiency in functional BAG3 protein, resulting in early onset heart failure that progresses rapidly. Despite current standard of care, almost 25% of patients require a heart transplant.
About Affinia Therapeutics
Affinia Therapeutics is a clinical-stage biotech company pioneering a transformational treatment paradigm shift to a new class of rationally designed gene therapies that treat rare and prevalent diseases. Affinia Therapeutics’ pipeline of first-in-class or best-in-class product candidates, initially in cardiovascular diseases, leverages its proprietary next-generation capsids, payloads, or manufacturing approaches and have shown efficacy, safety, and differentiation in relevant animal models.
